Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Panagiotis Apostolou


Annals of Oncology (2019) 30 (suppl_5): v574-v584. 10.1093/annonc/mdz257


P. Apostolou, D. Ntanovasilis, I. Papasotiriou

Author affiliations

  • Research & Development, Research Genetic Cancer Centre S.A., 53100 - Florina/GR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4945


Cancer of unknown primary origin (CUP) represents a metastatic cancer with unidentified primary origin. An efficient cancer treatment algorithm is based on detection and characterization of the tumor’s origin. CUP is characterized by chromosomal instability; therefore the detection of chromosomal aberrations might contribute in tumor characterization. aCGH combines DNA microarray with CGH providing better detection rates than conventional cytogenetic methods. The present study aimed to evaluate aCGH as a technique for detection the origin of tumor, based on liquid biopsy and particular in circulating tumor cells.


Blood samples were collected from five patients suffering from prostate (2), lung (2) and breast (1) cancer and five healthy individuals. CTCs isolated using enrichment protocols while CD45 (-ve) cells isolated from healthy individuals. In addition to patients’ samples, six commercial cancer cell lines provided by ECACC were used, representing prostate and lung cancer (DU145, 22Rv1, LNcaP, COLO699N, COR0L 105 and MOR). Genomic DNA extracted and aCGH experiments followed with Sureprint G3 platform (Agilent). The genes located in chromosomal aberrations were literately analyzed and potential cancer type suggested by another researcher. The researcher performed the analysis based only on aCGH raw data, ignoring the identity and medical history of all samples. Samples firstly analyzed based on normal vs cancer prediction and secondly whether the predicted type of cancer was correct.


The sensitivity was around 90% while the specificity was 80%. Among eleven cancer samples only one predicted as normal, as well as one normal sample predicted as cancer. As far as the cancer type prediction the positive predictive value was 90.1%. Only one sample categorized wrongly in total cancer samples.


aCGH is a powerful technique with potential of discrimination of cancer and healthy samples, but most important with ability to distinguish the type of cancer. The identification of primary origin of cancer is very important in CUP, since it is correlated with more efficient treatment algorithm. The above encouraging data from the combination of aCGH and liquid biopsy need to be validated in more samples and types of cancer so to be used at clinical level.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Research Genetic Cancer Centre S.A.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.